RxDoctor Payments Data

Maria Recurt, MD

Rheumatology · San Juan, PRNPI 1750340253

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,088 of the $5,516 with a category attached, or 74.1%. AbbVie accounts for 90.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $2,437 and has fallen 93.6% since, to $157 in 2025.

$5,516in general payments, 2019–2025

Across 23 payments — averaging $239.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • AstraZeneca$259
  • GSK$122
  • UCB, Inc.$108
  • Novartis$31
  • E.r. Squibb & Sons, L.L.C.$12

What the payments were for

  • Consulting fees$4,08874%
  • Travel & lodging$130%
  • Food & beverage$1,41526%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$4,984
AstraZeneca2$259
GSK1$122
UCB, Inc.1$108
Novartis2$31
E.r. Squibb & Sons, L.L.C.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,516 in reported general payments places this provider in the 65th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$40,935
Medicare patients
173
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab67$461,146
Enbrel SureclickEtanercept59$441,331
SimponiGolimumab27$193,686
EnbrelEtanercept24$177,437
Xeljanz XrTofacitinib Citrate23$161,011
RinvoqUpadacitinib21$157,637
Humira(Cf)Adalimumab21$144,240
Cimzia (2 Pack)Certolizumab Pegol12$92,656
ProliaDenosumab49$85,726
Orencia ClickjectAbatacept13$74,863
OrenciaAbatacept13$73,677
SynthroidLevothyroxine Sodium106$11,046
Lidocaine54$9,251
Diclofenac Potassium157$8,074
MethotrexateMethotrexate Sodium453$7,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf), Synthroid$4,984$312,924148 claims
UCB, Inc.Cimzia (2 Pack)$108$92,65612 claims
E.r. Squibb & Sons, L.L.C.Orencia$12$73,67713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →